Cantex has three product candidates in clinical development:



  • Azeliragon, an oral, small molecule, Phase 2-ready compound, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins produced by cancer cells
  • Although azeliragon did not show efficacy in a Phase 3 trial in Alzheimer’s disease, clinical safety data, with over 1500 individuals dosed, indicates high level of safety and tolerability
  • There has been extensive demonstration of pre-clinical efficacy of RAGE inhibition in animal models of diverse serious complications of cancer, including cancer bone pain, chemotherapy-induced cognitive impairment, chemotherapy-induced peripheral neuropathy, as well as cancer metastasis.
  • RAGE interactions with its ligands has also been implicated in pulmonary and other life-threatening complications of COVID-19 infection.
  • Cantex is planning Phase 2 trials in pancreatic cancer, pain associated with bone metastasis, and chemotherapy-induced cognitive impairment.



  • Blocks mechanisms essential for cancer cell survival
  • Phase 1/2 trial in relapsed/refractory myeloma is in progress
  • Other cancers that may be amenable to Dicopp® are under consideration.
  • Cantex owns issued and pending intellectual property for Dicopp®
  • Dicopp® is a 505(b)(2)product



  • Licensed to Chimerix in July 2019. Continued participation in development via Joint Development Committee.
    • Key deal terms
      • $30 million upfront
      • 10 million shares of Chimerix (NASDAQ:CMRX) common stock. We retain these 10 million shares.
      • Payments for achieving sales milestones and regulatory approvals totaling $587.5 million
      • Tiered double-digit royalties on net sales
  • Completed randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity
  • Phase 3 clinical trial in AML is in progress.